Company & Sponsor Intelligence
Ionis Pharmaceuticals, Inc.
Evidence-linked intelligence derived from the current NeuroRisk clinical research corpus. Coverage reflects indexed source data and is not a claim of complete company activity.
Request enterprise analysis →Indexed trials4
Recruiting3
Completed1
Countries2
Therapeutic footprint
epilepsymovement_disordersother_neurology
Indexed studies
NCT04165486Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of ION464 Administered to Adults With Multiple System Atrophy (HORIZON)
movement_disorders · AustriaPHASE1
movement_disorders · AustriaPHASE1
NCT03876522Natural History and Functional Status Study of Patients With Lafora Disease
epilepsy · United StatesCOMPLETED
epilepsy · United StatesCOMPLETED
NCT06153966PrProfile: A Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ION717
other_neurology · United StatesPHASE1, PHASE2
other_neurology · United StatesPHASE1, PHASE2
NCT07531745ASCEND: Safety and Tolerability of ION337 for the Treatment of Dravet Syndrome
epilepsy · United StatesPHASE1, PHASE2
epilepsy · United StatesPHASE1, PHASE2
Intelligence layer updated: 2026-10-29 06:17:44.639239+00:00
Enterprise intelligence
Compare sponsor activity, recruiting momentum, therapeutic exposure, geography and connected research signals across the neuroscience ecosystem.
Request comparative intelligence →